{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:28:23Z","timestamp":1788942503803,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jacc.2019.02.080","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T14:34:00Z","timestamp":1562078040000},"page":"699-711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Antithrombotics"],"prefix":"10.1016","volume":"74","author":[{"given":"Freek W.A.","family":"Verheugt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurri\u00ebn M.","family":"ten Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cuisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.02.080_bib1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/BF02114475","article-title":"Zur pathologischen physiologie des blutes","volume":"1","author":"Virchow","year":"1847","journal-title":"Virch Arch"},{"key":"10.1016\/j.jacc.2019.02.080_bib2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1161\/01.CIR.73.3.418","article-title":"Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death","volume":"73","author":"Davies","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.02.080_bib3","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM198405033101801","article-title":"Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death","volume":"310","author":"Davies","year":"1984","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ahj.2016.08.008","article-title":"A\u00a0critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease","volume":"181","author":"Welsh","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.02.080_bib5","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2174\/138161206776361318","article-title":"Biology and pharmacology of the platelet P2Y12 receptor","volume":"12","author":"Storey","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacc.2019.02.080_bib6","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.CIR.72.6.1177","article-title":"Clinical pharmacology of platelet cyclooxygenase inhibition","volume":"72","author":"Patrono","year":"1985","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.02.080_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12265-013-9524-6","article-title":"Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes","volume":"7","author":"Thomas","year":"2014","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.jacc.2019.02.080_bib8","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/eurheartj\/ehy066","article-title":"Antithrombotic\u00a0therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis","volume":"39","author":"Rocca","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.02.080_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/B978-0-12-386930-2.00006-9","article-title":"Genetics of response to antiplatelet therapy","volume":"124","author":"Thomas","year":"2014","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.jacc.2019.02.080_bib10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3109\/09537104.2013.842965","article-title":"Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study","volume":"25","author":"Storey","year":"2014","journal-title":"Platelets"},{"key":"10.1016\/j.jacc.2019.02.080_bib11","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.2174\/138161212803251989","article-title":"Development and clinical use of prasugrel and ticagrelor","volume":"18","author":"Ahmad","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacc.2019.02.080_bib12","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.02.080_bib13","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/j.1538-7836.2011.04419.x","article-title":"Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses","volume":"9","author":"Storey","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.02.080_bib14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/MCA.0000000000000541","article-title":"Effect of ticagrelor versus prasugrel on platelet reactivity: a meta-analysis","volume":"28","author":"Zhang","year":"2017","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.jacc.2019.02.080_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.118.034790","article-title":"Study of two dose regimens of ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease (STEEL-PCI)","author":"Orme","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.02.080_bib16","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jacc.2015.12.062","article-title":"Platelet inhibition with ticagrelor 60\u00a0mg versus 90\u00a0mg twice daily in the PEGASUS-TIMI 54 trial","volume":"67","author":"Storey","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.080_bib17","first-page":"555","article-title":"Dyspnoea management in acute coronary syndrome patients treated with ticagrelor","volume":"4","author":"Parodi","year":"2015","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.jacc.2019.02.080_bib18","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1538-7836.2005.01374.x","article-title":"New anticoagulants","volume":"3","author":"Weitz","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"Suppl","key":"10.1016\/j.jacc.2019.02.080_bib19","doi-asserted-by":"crossref","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","article-title":"The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Ansell","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2019.02.080_bib20","doi-asserted-by":"crossref","first-page":"97583","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.02.080_bib21","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2015.01.049","article-title":"Practical management of anticoagulation in patients with atrial fibrillation","volume":"65","author":"Kovacs","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.080_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7326\/0003-4819-30-1-80","article-title":"The use of the anticoagulants in the treatment of diseases of the heart and blood vessels","volume":"30","author":"Wright","year":"1949","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2019.02.080_bib24","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.080_bib25","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O\u2019Gara","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.080_bib26","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.02.080_bib27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A\u00a0randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.02.080_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0140-6736(02)09409-6","article-title":"Aspirin and Coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial","volume":"360","author":"Van Es","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.02.080_bib29","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.02.080_bib31","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.02.080_bib33","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib34","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib35","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent coronary syndrome","volume":"366","author":"Mega JL Braunwald","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.02.080_bib38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.02.080_bib39","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial Infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib40","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.080_bib41","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in ischemic events with ticagrelor in diabetic patients: from the PEGASUS-TIMI 54 Trial","volume":"67","author":"Bhatt","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.080_bib42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jacc.2017.11.050","article-title":"Ticagrelor for secondary prevention of atherothrombotic events in patients with multivessel coronary disease","volume":"71","author":"Bansilal","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.080_bib43","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1161\/CIRCULATIONAHA.117.032916","article-title":"Return of oral anticoagulation in chronic stable coronary disease","volume":"137","author":"Verheugt","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.02.080_bib44","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib45","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.02.080_bib46","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.02.080_bib47","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.02.080_bib48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ahj.2016.05.019","article-title":"Use of concomitant aspirin in patients with atrial fibrillation: findings from the ROCKET AF trial","volume":"179","author":"Shah","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.02.080_bib49","article-title":"Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 trial","volume":"5","author":"Xu","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2019.02.080_bib50","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.02.080_bib51","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.02.080_bib52","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib53","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib54","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with the EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.02.080_bib55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.02.080_bib56","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective 2018 update","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.02.080_bib57","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A\u00a0randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Sch\u00f6mig","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib58","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A\u00a0clinical trial comparing three antithrombotic drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib59","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.02.080_bib60","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST-segment elevation myocardial infarct","volume":"371","author":"Montalescot","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib61","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib62","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30\u00a0months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.080_bib63","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.02.080_bib64","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.02.080_bib65","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS","volume":"67","author":"Baber","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.080_bib66","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jama.292.3.362","article-title":"Early vs late administration of glycoprotein IIb\/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis","volume":"292","author":"Montalescot","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.02.080_bib67","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.02.080_bib68","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacc.2007.11.035","article-title":"Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis","volume":"51","author":"Ruiz-Nodar","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.080_bib69","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719354002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719354002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:23:41Z","timestamp":1760016221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719354002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0735109719354002"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.02.080","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotics","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.02.080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}